The New Frontier: Ibogaine in 2026 As we navigate 2026, the global perception of ibogaine has shifted from a fringe alternative to a serious subject of rigorous scientific inquiry. Once sidelined by its classification as a Schedule I substance, ibogaine is now at the center of a federal push to expand research into psychedelic-assisted therapies. […]